`
`U.S. Patent No. 8,475,832 (filed August 7, 2009)
`
`File History, U.S. Patent No. 8,475,832
`
`U.S. Patent No. 5,288,497 (“Stanley”)
`
`U.S. Patent No. 4,582,835
`
`U.S. Patent No. 7,357,891 (“Yang”)
`
`U.S. Patent App. No. US 2010/0087470
`
`U.S. Patent Application Publication 2005/0085440 (published April 21, 2005)
`(“Birch”)
`
`U.S. Patent Application Publication No. 2005/0037055 (“the ’055 publication”)
`
`WO 2008/025791 (published March 6, 2008) (“Oksche”)
`
`WO 2008/040534 (published April 10, 2008) (“LabTec”)
`
`Suboxone® Label
`
`Suboxone® Tablet Summary Basis of Approval (“SBOA”)
`
`European Medicines Agency Initial Marketing-Authorisation Document, Scientific
`Discussion, Oct. 19, 2006 for Suboxone sublingual tablets (“EMEA”)
`
`Center for Drug Evaluation and Research, Approval Package for App. No. 22-
`410/S006/S007 (approval date 8/10/12) (“Film Approval Package”).
`J.P. Cassidy et al., Controlled Buccal Delivery of Buprenorphine, 25 J. Controlled
`Release 21 (1993) [“Cassidy”]
`Rex M. C. Dawson et al., Data for Biochemical Research (3d ed. 1986)
`
`Domenic A. Ciraulo et al., Pharmacokinetics and Pharmacodynamics of Multiple
`Sublingual Buprenorphine Tablets in Dose-Escelation Trials, 46 J. Clinical
`Pharmacology 179 (2006)
`
`C. Nora Chiang & Richard L. Hawks, Pharmacokinetics of the Combination Tablet
`of Buprenorphine and Naloxone, 70 Drug & Alcohol Dependence S39 (2003)
`
`
`
`TEVA EXHIBIT 1026
`TEVA PHARMACEUTICALS USA, INC. V. RB PHARMACEUTICALS LTD.
`
`
`
`
`
`Materials Considered by Nandita Das, Ph.D.
`
`Campbell et al., The History of the Development of Buprenorphine as an Addiction
`Therapeutic, 1248 Ann. N.Y. Acad. Sc. (Issue: Addiction Reviews), 124 (2012)
`(“Campbell”)
`
`Bullingham et al., Sublingual Buprenorphine Used Postoperatively: Clinical
`Observations and Preliminary Pharmacokinetic Analysis, 12 Br. J. Clinical
`Pharmacology 117 (1981)
`Encyclopedia of Pharmaceutical Technology, 2nd ed., Vol. I, Drug Delivery—
`Buccal Route (McElnay et al.) (“McElnay”)
`
`Inter partes Review (“BDSI”) of U.S. Pat. No. 8,475,832, Decl. by Maureen
`Reitman, SC.D., Ex. 100_at 3 (“Reitman Decl.”).
`
`Parkhurst A. Shore et al., The Gastric Secretion of Drugs: A pH Partition
`Hypothesis, 119 J. Pharmacology Exp. Ther. 361 (1957)
`
`
`
`
`
`2
`
`TEVA EXHIBIT 1026
`TEVA PHARMACEUTICALS USA, INC. V. RB PHARMACEUTICALS LTD.